- Home
- MTNB vs SILO Comparison
MTNB vs SILO Comparison
Compare MTNB & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTNB | SILO |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 3.9M |
| IPO Year | 2014 | 2011 |
Fundamental Metrics
Financial Performance| Metric | MTNB | SILO |
|---|---|---|
| Price | $0.59 | $0.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.5K | ★ 408.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.83 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $119,750.00 | $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.47 | $0.22 |
| 52 Week High | $3.09 | $1.44 |
Technical Indicators
Market Signals| Indicator | MTNB | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 44.98 | 47.76 |
| Support Level | $0.57 | $0.33 |
| Resistance Level | $0.65 | $0.45 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 30.46 | 66.98 |
Price Performance
Historical ComparisonAbout MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.